Childhood absence epilepsy that also involves generalized tonic-clonic seizures (GTCS) represents a specific clinical subgroup. Not all first-line antiepileptic options cover both seizure types, which shapes the treatment sequence — and determines what the next step is when the initial approach falls short.
Childhood absence epilepsy with the occurrence of a generalized tonic-clonic seizure. The presence of GTCS is clinically significant: it narrows which agents are appropriate at each treatment line, because some options do not provide coverage beyond absence seizures alone.
Valproic acid (VPA) is the recommended first-line agent in this scenario. Escalation to the next treatment line is triggered when VPA fails to achieve the required goals: complete freedom from absence seizures (confirmed by both parent report and EEG), or when valproate serum levels do not reach the established therapeutic target range.
When Valproic acid has not met these targets, a specific alternative oral antiepileptic agent is introduced under a structured titration protocol. The therapeutic goals remain the same: freedom from absence seizures and confirmation that drug levels are within the therapeutic range. The complete protocol — including the specific agent, initiation schedule, and monitoring criteria — is available in full below.
VPA is the drug of choice as initial monotherapy in CAE when a generalized tonic–clonic seizure has occurred, because ETX is not effective against seizure types beyond absence seizures.
Persistent seizures or adverse effects on ETX and VPA monotherapy, or contraindication to VPA: Treat with LTG.
Serum levels of LTG considered to be in the therapeutic range are between 5 and 15 µg/mL, though dose-dependent side effects may emerge when levels exceed 10–12 µg/mL.
View source ↗